ROCHESTER, N.Y. and RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Aug. 29, 2006--Bausch & Lomb (NYSE:BOL) and Talecris Biotherapeutics announced today that Talecris has granted an exclusive worldwide license to Bausch & Lomb for recombinant Plasmin technology for use in ophthalmology. The companies will co-develop rPlasmin, a recombinant derivative of the human blood component Plasmin, which Bausch & Lomb believes may have potential for use in developing novel therapies for ocular conditions. Talecris is pursuing development of the technology in non-ocular applications, specifically to dissolve blood clots in veins and arteries.
